The assessment of impurities for genotoxic potential and subsequent control in drug substance and drug product.

The strategies implemented at Eli Lilly and Company to address European Medicines Agency and US Food and Drug Administration requirements governing the control of genotoxic impurities (GTIs) are presented. These strategies were developed to provide understanding with regard to the risk and potential liabilities that could be associated with developmental and marketed compounds. The strategies systematize the assessment of impurities for genotoxic potential, addressing both actual and potential impurities. Timing of activities is designed to minimize impact to development timelines while building a data package sufficient to either discharge the risk of potential GTI formation or support the implementation of a specification necessary for long-term control. This article presents the background associated with GTI control, the types of impurities that should be assessed, and the actions to be taken when an impurity is found to be genotoxic. A systematic approach to define potential degradation products derived from stress-testing studies is outlined with a proposal to perform a genotoxic risk assessment on these impurities. Finally, an Arrhenius-based strategy is proposed for a rapid assessment of the likelihood of potential degradation impurities to form in the commercial drug product formulation. Importantly, this article makes a proposal for discharging the risk of a potential GTI with supporting data.

[1]  D. Snodin.  Genotoxic Impurities: From Structural Alerts to Qualification , 2010 .

[2]  Patrick Lukulay,et al.  Improved Protocol and Data Analysis for Accelerated Shelf-Life Estimation of Solid Dosage Forms , 2007, Pharmaceutical Research.

[3]  S. R. Thatcher,et al.  Pharmaceutical photostability : A technical guide and practical interpretation of the ICH guideline and its application to pharmaceutical stability : Part II , 2001 .

[4]  Andrew Teasdale,et al.  A Tool for the Semiquantitative Assessment of Potentially Genotoxic Impurity (PGI) Carryover into API Using Physicochemical Parameters and Process Conditions , 2010 .

[5]  Andrew Teasdale,et al.  Genotoxic Impurities: Strategies for Identification and Control , 2011 .

[6]  David L. Varie,et al.  Approaches to Assessment, Testing Decisions, and Analytical Determination of Genotoxic Impurities in Drug Substances , 2009 .

[7]  Nigel Greene,et al.  In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: an industry survey. , 2012, Regulatory toxicology and pharmacology : RTP.

[8]  Karen M. Alsante,et al.  Degradation and Impurity Analysis for Pharmaceutical Drug Candidates , 2011 .

[9]  D. Brusick.  A perspective on testing of existing pharmaceutical excipients for genotoxic impurities. , 2009, Regulatory toxicology and pharmacology : RTP.

[10]  Dan W. Reynolds,et al.  Available guidance and best practices for conducting force degradation studies , 2002 .

[11]  D. Snodin,et al.  Guidelines and pharmacopoeial standards for pharmaceutical impurities: overview and critical assessment. , 2012, Regulatory toxicology and pharmacology : RTP.

[12]  Nigel Greene,et al.  The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development. , 2006, Regulatory toxicology and pharmacology : RTP.

[13]  A. D. Rodrigues,et al.  Estimation of the extent of in vivo formation of a mutagenic aromatic amine from a potent thyromimetic compound: correlation of in vitro and in vivo findings. , 2011, Chemical research in toxicology.

[14]  G Würtzen,et al.  Threshold of toxicological concern for chemical substances present in the diet. Report of a workshop, 5-6 October 1999, Paris, France. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[15]  Romualdo Benigni,et al.  Structure alerts for carcinogenicity, and the Salmonella assay system: a novel insight through the chemical relational databases technology. , 2008, Mutation research.

[16]  H. Gally,et al.  Overall impact of the regulatory requirements for genotoxic impurities on the drug development process. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  Derek Robinson,et al.  Control of Genotoxic Impurities in Active Pharmaceutical Ingredients: A Review and Perspective , 2010 .

[18]  Gerhard Nahler,et al.  International Conference on Harmonisation (ICH) , 2009 .

[19]  David Q. Liu,et al.  Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process. , 2009, Journal of pharmaceutical and biomedical analysis.

[20]  T. McGovern,et al.  Regulation of genotoxic and carcinogenic impurities in drug substances and products , 2006 .

[21]  Karen M. Alsante,et al.  The role of degradant profiling in active pharmaceutical ingredients and drug products. , 2007, Advanced drug delivery reviews.

[22]  Steven W. Baertschi,et al.  Pharmaceutical Stress Testing : Predicting Drug Degradation , 2005 .

[23]  R. Adami,et al.  Accelerated aging: prediction of chemical stability of pharmaceuticals. , 2005, International journal of pharmaceutics.

[24]  Ronald D Snyder,et al.  An update on the genotoxicity and carcinogenicity of marketed pharmaceuticals with reference to in silico predictivity , 2009, Environmental and molecular mutagenesis.

[25]  N V V S S Raman,et al.  Strategies for the identification, control and determination of genotoxic impurities in drug substances: a pharmaceutical industry perspective. , 2011, Journal of pharmaceutical and biomedical analysis.

[26]  S Gaisford,et al.  Pharmaceutical stress testing , 2005 .

[27]  C. Riley,et al.  Prediction of Drug Degradation Pathways leading to Structural Alerts for Potential Genotoxic Impurities , 2010 .

[28]  David K. Robbins,et al.  Risk Assessment of Genotoxic Impurities in Marketed Compounds Administered over a Short-Term Duration: Applications to Oncology Products and Implications for Impurity Control Limits , 2010 .

[29]  R. Tennant,et al.  Chemical structure, Salmonella mutagenicity and extent of carcinogenicity as indicators of genotoxic carcinogenesis among 222 chemicals tested in rodents by the U.S. NCI/NTP. , 1988, Mutation research.

[30]  W. Lutz.  The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination? , 2009, Toxicology letters.

[31]  Patrick Sandra,et al.  A Detailed Study of Sulfonate Ester Formation and Solvolysis Reaction Rates and Application toward Establishing Sulfonate Ester Control in Pharmaceutical Manufacturing Processes , 2010 .

[32]  Lutz Müller,et al.  A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. , 2006, Regulatory toxicology and pharmacology : RTP.